GlassScriptPhysician profile
David B Arconti
NPI 1225337264
$7,772.66
in general payments reported to CMS, 2019-2025
27 companies · $37.10 in 2025
The $37.10 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,726 · 2022: $3,187 · 2023: $1,740 · 2024: $81.84 · 2025: $37.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,859.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,026.43 | 2021-2024 | Prolia, Enbrel, Evenity |
| Abbvie INC. | $1,052.62 | 2021-2023 | |
| Janssen Biotech, INC. | $861.17 | 2021-2023 | Tremfya |
| Novartis Pharmaceuticals Corporation | $629.82 | 2021-2023 | |
| Ucb, INC. | $589.33 | 2021-2023 | Cimzia |
| Pfizer INC. | $466.06 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $306.27 | 2021-2023 | Saphnelo |
| Lilly USA, LLC | $277.84 | 2021-2023 | Taltz |
| Mallinckrodt Hospital Products INC. | $246.96 | 2021-2023 | Acthar |
| Horizon Therapeutics Plc | $237.77 | 2021-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $211.60 | 2021-2025 | Orencia |
| Aurinia Pharma U.S., INC. | $174.41 | 2022-2023 | Lupkynis |
| Glaxosmithkline, LLC. | $150.22 | 2021-2023 | Benlysta, Nucala |
| Organon LLC | $86.60 | 2021-2023 | Renflexis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.44 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $59.95 | 2021-2023 | Strensiq |
| Genentech USA, INC. | $59.01 | 2021-2022 | |
| Cumberland Pharmaceuticals, INC. | $48.67 | 2022 | |
| Depuy Synthes Sales INC. | $37.00 | 2021 | |
| Ani Pharmaceuticals, INC. | $28.66 | 2022 | |
| Tersera Therapeutics LLC | $28.33 | 2022 | |
| Fresenius Kabi USA, LLC | $24.91 | 2023 | Idacio |
| Octapharma USA, INC. | $23.94 | 2022 | |
| Daiichi Sankyo INC. | $23.92 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $23.00 | 2021 | |
| Radius Health, INC. | $19.94 | 2021 | |
| Collegium Pharmaceutical, INC. | $17.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Arconti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.